RxDoctor Payments Data

Ashley Kirkpatrick

Family · Springfield, ILNPI 1073148375

Payments from drug & device makers

$1,571in general payments, 2019–2025

Across 34 payments — averaging $46.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$667
  • Astellas Pharma US Inc$254
  • Antares Pharma, Inc.$132
  • Endo Pharmaceuticals Inc.$125
  • Endo USA, Inc.$125
  • Coloplast$94
  • plus $173 from 7 others

What the payments were for

  • Travel & lodging$29819%
  • Food & beverage$1,20577%
  • Education$684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,571 in reported general payments places this provider in the 80th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$140,545
Medicare patients
436
Services billed
32,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron186$118,419
GemtesaVibegron49$36,546
Testosterone82$15,561
Mirabegron ErMirabegron23$15,241
Testosterone Cypionate282$9,738
Tamsulosin Hcl569$9,715
Solifenacin Succinate32$2,457
Oxybutynin Chloride ErOxybutynin Chloride87$2,443
Finasteride203$2,305
Trospium Chloride41$1,877
Potassium Citrate ErPotassium Citrate12$1,061
Alfuzosin Hcl ErAlfuzosin Hcl34$637
Allopurinol24$85
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$67
Anastrozole22$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$254$118,419186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,941 family providers in Illinois.

Other family in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →